Abstract: A lubricant composition for use in a rotary vane compressor has a base oil component that comprises an alkylbenzene as a major component thereof and a polyol ester as a minor component thereof. In particular, the base oil component comprises at least 55% by weight of alkylbenzene and at most 45% by weight of a polyol ester, more preferably between 55% and 75% by weight of alkylbenzene and between 45% and 25% by weight of polyol ester and, especially, between 60% and 75% by weight of alkyl benzene and between 45% and 25% by weight of polyol ester.

Abstract: Ophthalmic compositions such as eye drop and contact lens treating solutions include a polycationic material to enhance antimicrobial efficacy against protozoans such as acanthamoebae. One preferred class of polycationic materials is cationic cellulose derivatives.

Abstract: Compositions, methods, and kits for caring for, treating, conditioning or durable conditioning of at least one keratinous fiber comprising at least one silicone compound comprising at least one phosphate group compound and at least one amine compound comprising greater than three amino groups, wherein the amino groups are identical or different.

Abstract: The present invention features a cleansing composition containing (i) a surfactant, (ii) a legume product, and (iii) a cosmetically active organic acid or a cosmetically acceptable salt or ester thereof, and the use thereof in cleansing the skin.

Abstract: A process for making a chemical composition includes the steps of mixing 200-800 parts by volume of petroleum solvent with 10-500 parts by volume of normal paraffin or isoparaffin at room temperature to form a solvent paraffin mixture. A microcrystalline wax is heated to between 180-200 degrees Fahrenheit until melted and 90-700 parts by volume of melted microcrystalline wax is vigorously mixed with the normal paraffin or isoparaffin mixture to form a creamy liquid useful as a hand cleaner and paint remover as well as a fire starter.

Abstract: A composition for stripping photoresist, methods of preparing and forming the same, a method of manufacturing a semiconductor device using the composition, and a method of removing a photoresist pattern from an underlying layer using the composition, where the composition may include an ethoxy N-hydroxyalkyl alkanamide represented by the formula, CH3CH2—O—R3—CO—N—R1R2OH, an alkanolamine and a polar material. Raw materials of alkyl alkoxy alkanoate, represented by a chemical formula of R4—O—R3—COOR5, and alkanolamine, represented by a chemical formula of NHR1R2OH, may be mixed to form a mixture, which is stirred and cooled to obtain the composition. The composition may balance exfoliation and dissolution of photoresist patterns, and may potentially eliminate thread-type residues from remaining on a surface of an underlying layer after removing the photoresist patterns.

Abstract: A photochromic photo resist composition that changes color on exposure to radiation; thereby providing a distinctive visible interface between exposed and non-exposed areas. In the composition, 0.2-5% of a photochromic dye solution is prepared in hot toluene. Twenty parts of the dye solution is then added slowly to the photo resist under mild agitation, thereby forming the color changing photo resist. The color changing property of the photo resist facilitates alignment of mask patterns in continuous patterning of images on a large substrate.

Abstract: A non-liquid, liquid, liquid-gel or gelled fabric care composition and method of use comprising:

Abstract: The invention relates to a washing, rinsing or cleaning agent dose comprising a fully or partially water-soluble coating in the form of a capsule, a ball or a bag. Said coating completely surrounds a liquid-based formulation of at least one washing, rinsing or cleaning active ingredient having a crushing resistance of >1 N at 23° C. The invention also relates to a method for producing one such washing, rinsing or cleaning agent dose, in addition to a method for washing, rinsing or cleaning using said washing, rinsing or cleaning agent dose.

Abstract: The present invention relates to fabric care compositions having enhanced fabric color protection, said compositions comprising a bleach scavenging system comprising:

Abstract: A manual spray cleaner for removing dirt and stains from fabrics and carpets comprising a spray bottle having two separate chambers and a single dispensing spray outlet for dispensing controlled amounts of liquids from each of the chambers. One of the chambers has a fabric/carpet cleaning composition therein and the other chamber has an oxidizing composition that enhances the cleanability of the fabric/carpet cleaning composition. The fabric/carpet cleaning composition and the oxidizing composition are simultaneously drawn from their respective chambers and mixed together at the time that they are dispensed from the spray bottle. At least one of the oxidizing composition and the fabric/carpet cleaning composition includes a fabric/carpet protectant. The two compositions are mixed before or after they are sprayed from the bottle. The two compositions can be pressurized with an aerosol propellant or drawn from their respective chambers by a mechanical pump.

Abstract: A method for manufacturing liquid gel anhydrous organic solvent compositions comprising sodium polyphosphate hexahydrate and a water-soluble dye which minimizes excessive pouch swelling and provides superior product color aesthetics.

Abstract: The invention relates to highly ethoxylated hydroxy mixed ethers combined with washing, rinsing and cleaning agents, and the use of such hydroxy mixed ethers as anti-foaming agents in washing, rinsing and cleaning agents.

Abstract: The present invention relates to a substantially dry article containing an insoluble substrate, at least one oxidizing agent, and at least one reducing agent, wherein the article is exothermic when wet with water and the use thereof.

Abstract: A perfume composition comprises: e) at least about 25% by weight in total of at least five selected relaxing fragrance materials (R); f) optionally up to about 45% by weight in total of non-relaxing fragrance materials (NR), provided that the ratio by weight of R to NR is at least 0.75; g) optionally up to about 75% by weight in total of neutral fragrance materials (N); h) optionally up to about 25% by weight of other fragrance materials (M) provided that the weight ratio R to (M+NR) at least 0.75; and wherein all percentages are based on total weight of the fragrance materials consisting the perfume composition.

Abstract: Therapeutic composition and method for treating and preventing HIV infection, the composition comprising and active substance, which is capable of interacting with a complex of cell-uPAR-uPA-gp120-HIV so as to prevent or reduce the internalisation of HIV into the cell.

Abstract: The present invention provides elastomeric copolyester amides, elastomeric copolyester urethanes, and methods for making the same. The polymers that are based on &agr;-amino acids and possess suitable physical, chemical and biodegradation properties. The polymers are useful as carriers of drugs or other bioactive substances. The polymers can be linked, intermixed, or a combination thereof, to one or more drugs.

Abstract: The present invention describes in particular a method for stabilizing a pharmaceutical composition by contacting said composition with a polymeric material comprising in particular an ethylene oxide sterilization step.

Abstract: A method and nutrient supplement composition for nocturnal administration to human subjects where the nutrient supplement composition includes both a sustained timed release portion and a rapid release portion, both portions containing a mixture of edible food proteins and edible amino acid building blocks with a portion of these key components being microencapsulated for sustained timed release in a the human body during the growth hormone spikes that generally occur during nocturnal sleep.

Abstract: A crystalline salt according to formula (1): or the opposite enantiomer thereof, wherein X+ is a cation. Such salts are useful in preparing chiral scaffolds, in particular of formulae (a)-(d).

Abstract: FKS06 and geldanamycin promote nerve regeneration by a common mechanism that involves the binding of these compounds to polypeptide components of steroid receptor-complexes other than the steroid hormone binding portion of the complex (FKBP52 and hsp90, respectively). These and other agents cause hsp90 dissociation from steroid receptor complexes or block association of hsp90 with steroid receptor complexes.

Abstract: The invention relates to a pharmaceutical preparation comprising levothyroxine sodium, gelatine and fillers, which is free of organic solvent residues, and to processes for its production.

Abstract: The present invention relates to methods of treating neurodegenerative diseases with the neuroprotective agents of Formulas I-IV and XII and the other compounds described herein. The neuroprotective agents inhibit nitric oxide synthase enzymes and in particular nitric oxide synthase III (NOS III) and can be used to treat Alzheimer's disease.

Abstract: The invention provides methods and compositions that are useful for adhering biological and/or synthetic tissues, sealing fluid and/or gaseous leaks in biological and/or synthetic tissues, and preparing implants useful for delivery of a bioactive molecule such as a drug, for bulking applications, or for tissue prostheses. The present invention also relates to bio-erodable adhesive or occluding compositions and methods of using the same.

Abstract: A brain-protective agent containing an NF-&kgr;B decoy. In brain diseases, the brain can be particularly effectively protected against brain disorders (for example, cerebral vasospasm following a subrachnoidal hemorrhage and apoptosis of the nerve cells following a cerebrovasucular accident or serious head injury) caused by the undesired activation of cytokines or cell adhesion factors which are regulated by NF-&kgr;B by administering the brain-protective agent containing an NF-&kgr;B decoy, i.e., a compound antadonistic specifically to a nucleic acid to which NF-&kgr;B binds.

Abstract: Provided is an insulin-containing granulated composition for nasal administration comprising a crystalline cellulose aggregate having a specific particle diameter distribution as a carrier. Such granulated composition for nasal administration can efficiently increase a blood insulin concentration.

Abstract: Novel compositions for treating skin defects and effecting desired cosmetic changes by way of soft tissue augmentation, combine at least one soft tissue filler and at least one peptide copper complex. Typically, the compositions are suitable for injection into skin areas in need of such treatment. Also disclosed are methods for treating skin defects and effecting desired cosmetic changes. One disclosed method employs the disclosed compositions wherein the soft tissue fillers and peptide copper complexes are combined. Other disclosed methods combine the soft tissue fillers and peptide copper complexes during application of the method itself by way of injection, or a combination of injection and topical application, of the fillers and complexes.

Abstract: This invention concerns a method of making an anti-infective composition for oral administration using an agent selected from the group consisting of lactoferrin protein and lysozyme protein. The method comprises three steps. The nucleic acid, which encodes a lactoferrin or lysozyme protein, is expressed in a monocot seed. The protein is isolated from the seed. This protein isolation compromises greater than 3% of the total soluble protein in the monocot seed. The protein is then formulated for oral administration.

Abstract: Disclosed are compositions and methods for enhancing in vivo uptake and tissue distribution in animals of peptide nucleic acids. The peptide nucleic acids include cationic conjugates attached thereto. The cationic conjugated peptide nucleic acids exhibit enhanced uptake and tissue distribution.

Abstract: New uses of proteoglycans to bind and present growth factors, methods of accelerating wound, tissue or bone repair using such proteoglycans, pharmaceutical compositions of such proteoglycans, and scaffolds coated with such proteoglycans are disclosed. The proteoglycan of the invention is derived from domain I or perlecan.

Abstract: Ophthalmic compositions include a polycation material to enhance antimicrobial efficacy against bacteria such as E. coli. The compositions include eye drop and contact lens treating solutions. A preferred polycation material is cationic cellulose derivatives.

Abstract: The invention relates to a human GHRH-binding protein (human Growth Hormone-releasing hormone). Said protein, which is obtained from the Pilocarpus Heterophyllus plant, can be used to prepare medicaments intended to antagonise the effects of GHRH and to treat proliferative diseases (particularly cancer), acromegaly or diabetic nephropathies and retinopathies.

Abstract: A method and composition for treating a host infected with flavivirus or pestivirus comprising administering an effective flavivirus or pestivirus treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.

Abstract: The present invention provides stable compounds prepared from boronic acid and lyophilized compounds thereof of the formula (1): 1

Abstract: The invention provides a method of inhibiting the transition of free HIV virus carrying an envelope glycoprotein gp120/gp160 through the cellular mucosal barrier of an organism, wherein said glycoprotein is blocked by increasing in the region of said mucosal barrier the concentration of compounds comprising an oligomannosyl glycan residue and/or compounds comprising mimic molecules of an oligomannosyl glycan, wherein the link of said glycoprotein to said HIV virus remains essentially unaffected. The invention further provides useful pharmaceutical compositions and methodes for preventing an HIV infection and/or treating an HIV infection.

Abstract: A novel cyclic peptide having an antifungal activity, its pharmacologically acceptable salts and antifungal medicinal compositions containing the same.

Abstract: The present invention discloses a composition comprising a cyclosporin A derivative having an excellent hair revitalizing activity as an active ingredient, and more particularly, a composition comprising cyclosporin A 7-thioamide produced by chemical derivatization of cyclosporin A as an active ingredient for promoting hair growth.

Abstract: The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Example of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders.

Abstract: The present invention relates to active agent delivery systems and more specifically to compositions that comprise amino acids, as single amino acids or peptides, covalently attached to active agents and methods for administering conjugated active agent compositions.

Abstract: This invention relates to a method for treating a tendon or ligament disorder, comprising the step of administration of a pharmaceutical or veterinary composition of IGF to the affected area of a subject in need of such treatment. The tendon or ligament disorder may be the result of a traumatic, exercise-related or overuse injury, or may be the result of, or associated with, a pathological condition. In preferred embodiments the traumatic or exercise-related injury is a ruptured tendon or ligament; a severed tendon or ligament; a tendon or ligament avulsion; a tendon or ligament sprain; limping or lameness; or the pathological condition is a disease, such as an inherited disease, an endocrinological or metabolic condition, an infectious disease, or a disease attributed to inflammation of the tendon, ligament or surrounding tissue. The invention further relates to compositions for the treatment of these conditions.

Abstract: Compositions and methods are disclosed for administration of synergistic levels of a diuretic and a natriuretic peptide, especially a recombinant form of human BNP, or hBNP. These compositions and methods are useful for the treatment of congestive heart failure.

Abstract: The present invention relates to peptides which are highly biologically and pharmacologically active as therapeutic drug for the treatment of diseases related to hypertension, especially in medical interventions involving dilatation and remodelling of arterial blood vessels, either in the pulmonary or in the systemic circulation. The peptides which can be used according to the invention for the treatment of said diseases comprises at least one specific highly conservative amino acid residue sequence which seem to play an important role in connection with pulmonary and arteriolar hypertension events. It could be shown that the known naturally occurring peptides “vasoactive intestinal peptide (VIP)” and pituitary adenylate cyclaseactivating polypeptide (PACAP)”, having these specific sequences are potent drugs which can be successfully used for treatment of primary pulmonary hypertension (PPH), secondary pulmonary hypertension (SPH), and hypertension of the systemic circulation.

Abstract: This invention relates to novel fusion proteins which are comprised of a targeting protein that binds tissue factor (TF), which is operably linked to the thrombomodulin (TM) EGF456 domain alone or in combination with at least one other TM domain selected from the group consisting of the N-terminal hydrophobic region domain, the EGF123 domain, the interdomain loop between EGF3 and EGF4, and the O-glycosylated Ser/Thr-rich domain, or analogs, fragments, derivatives or variants thereof. The fusion protein binds at the site of injury and prevents the initiation of thrombosis. The fusion protein can be used to treat a variety of thrombotic conditions including but not limited to deep vein thrombosis, disseminated intravascular coagulation, and acute coronary syndrome.

Abstract: Whey protein is hydrolyzed with hydrolase so that a rate of hydrolysis is preferably 20 to 30%. A fraction, which has molecular weights above 10,000 daltons, is removed from a resultant hydrolysate by means of an ultrafiltration method to obtain a whey protein hydrolysate which is used as an active ingredient of an interleukin-18 inducer.

Abstract: The present invention relates to polypeptides to be administered especially to humans and in particular for therapeutic use. The polypeptides are modified polypeptides whereby the modification results in a reduced propensity for the polypeptide to elicit an immune response upon administration to the human subject. The invention in particular relates to the modification of keratinocyte growth factor (KGF) to result in keratinocyte growth factor (KGF) proteins that are substantially non-immunogenic or less immunogenic than any non-modified counterpart when used in vivo.

Abstract: Compositions, kits and methods are provided for promoting general health or for prevention or treatment of diseases by using novel recombinant fusion proteins of human serum albumin (HSA) and bioactive molecules. The bioactive molecules may be a protein or peptide having a biological function in vitro or in vivo, and preferably, having a therapeutic activity when administered to a human. By fusing the bioactive molecule to HSA, stability of the bioactive molecule in vivo can be improved and the therapeutic index increased due to reduced toxicity and longer-lasting therapeutic effects in vivo. In addition, manufacturing processes are provided for efficient, cost-effective production of these recombinant proteins in yeast.

Abstract: Compounds that are ligands for the growth hormone secretagogue receptor type 1A (GHS-R 1A), as well as pharmaceutically acceptable salts of such compounds, are useful for the manufacture of medicaments for the regulation of food intake.

Abstract: Provided is a pharmaceutical composition comprising a solution comprised of synthetic peptide in a final concentration of not less than 70 mg/ml in admixture with a polyol; wherein the synthetic peptide is an HIV fusion inhibitor, and wherein the polyol is in a final concentration of no less than 5 weight % and no more than 75 weight % of the pharmaceutical composition. Also provided is a synthetic peptide-containing pharmaceutical composition as a unit dose comprising an aqueous formulation comprised of synthetic peptide in a final concentration of not less than 70 mg/ml in admixture with a polyol; wherein the synthetic peptide is an HIV fusion inhibitor, and wherein the polyol is in a final concentration of no less than 5 weight % and no more than 75 weight % of the pharmaceutical composition. Further provided is a method of treating HIV infection by administering to an HIV-infected individual a pharmaceutical composition according to the present invention.

Abstract: The present invention is directed to secreted and transmembrane polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: The invention is directed to liquid and lyophilized forms of Keratinocyte Growth Factor-2 (KGF-2) and derivatives thereof. This invention further relates to the formulation of KGF-2 for therapeutic use, for example, to promote or accelerate wound healing.